Renovo co-founder to leave next year

ONE of the leading figures behind the rise of leading Manchester-based biotech company Renovo is standing down, it was announced today.

Dr Sharon O’Kane, who co-founded the pioneering anti-scarring drug developer, will leave her post as executive director and chief scientific officer next February to pursue other business interests.

She said today: “I have greatly enjoyed helping to build Renovo from its foundation 10 years ago through to the successful public company it is today. I intend to use this experience to help start and build other companies and to take up some non-executive director positions.

“I am confident that Renovo has a bright future which I will follow with interest.”
 
Rodger Pannone, chairman of Renovo, said: “The board would like to thank
Sharon for her significant contribution to the success of the business over the last 10 years, during which time Renovo has developed from a small early stage private company to a larger public entity with a late stage pipeline of drugs for the prevention and reduction of scarring.

“While we will be extremely sorry to see Sharon leave, we understand that she wishes to put her experience to use in growing and advising other companies. We wish her well for the future.”